Vivos Therapeutics to acquire stake in SOD Sciences for $12M preferred stock
Vivos Therapeutics agreed to acquire approximately 11% equity and a 50% interest in new IP from SOD Sciences, and will issue $12M in convertible preferred stock as consideration.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed